effect overlay
activetrials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson’s Disease
 

HREC: 2020.027
Principal Investigator: Dr Andrew Evans
Coordinator contact: Fiona Leen
Funding: Commercial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults with Motor Fluctuations
 

HREC: 2020.077
Principal Investigator: Dr Andrew Evans
Coordinator contact: Fiona Leen
Funding: Commercial

Clinicodiagnostic features and treatment outcomes in laryngeal movement disorders
 

HREC: 2020.134
Principal Investigator: Dr Andrew Evans
Coordinator contact: Dr Belinda Cruse
Funding: Non-Commercial

An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson's Disease
 

HREC: 2020.172
Principal Investigator: Dr Andrew Evans
Coordinator contact: Grace Edwards
Funding: Commercial
Movement Disorders

DBS Registry of Outcomes for Indications over Time: Abbott's market-released DBS systems study
 

HREC: 2020.192
Principal Investigator: Dr Andrew Evans
Coordinator contact: Mr Girish Nair
Funding: Commercial